The prognostic role of galectin-3 and endothelial function in patients with heart failure.
ejection fraction
endothelial function
galectin-3
heart failure
prognosis
Journal
Cardiology journal
ISSN: 1898-018X
Titre abrégé: Cardiol J
Pays: Poland
ID NLM: 101392712
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
02
2022
accepted:
06
05
2022
revised:
12
04
2022
medline:
8
11
2023
pubmed:
18
8
2022
entrez:
17
8
2022
Statut:
ppublish
Résumé
Heart failure (HF) is nowadays classified as HF with reduced ejection fraction (HFrEF), HF with mildly reduced EF (HFmrEF), and HF with preserved EF (HFpEF). Endothelial dysfunction (assessed by flow-mediated dilatation [FMD]), increased arterial stiffness (assessed by carotid-femoral pulse-wave velocity [PWV]), and galectin-3, a biomarker of myocardial fibrosis, have been linked to major adverse cardiovascular events (MACE) in patients with ischemic HF. In this study we prospectively enrolled 340 patients with stable ischemic HF. We assessed the brachial artery FMD, carotid-femoral PWV, and galectin-3 levels, and patients were followed up for MACE according to HF group. Interestingly, the FMD values exhibited a stepwise improvement according to left ventricular ejection fraction (LVEF) (HFrEF: 4.74 ± 2.35% vs. HFmrEF: 4.97 ± 2.81% vs. HFpEF: 5.94 ± ± 3.46%, p = 0.01), which remained significant after the evaluation of possible confounders including age, sex, cardiovascular risk factors, and number of significantly stenosed epicardial coronary arteries (b coefficient: 0.990, 95% confidence interval: 0.166-1.814, p = 0.019). Single-vessel coronary artery disease was more frequent in the group of HFpEF (HFrEF: 56% vs. HFmrEF: 64% vs. HFpEF: 73%, p = 0.049). PWV did not display any association with LVEF. Patients who presented MACE exhibited worse FMD values (4.51 ± 2.35% vs. 5.32 ± 2.67%, p = 0.02), and the highest tertile of galectin-3 was linked to more MACEs (36% vs. 5.9%, p = 0.01). Flow-mediated dilatation displayed a linear improvement with LVEF in patients with ischemic HF. Deteriorated values are associated with MACE. Higher levels of galectin-3 might be used for risk stratification of patients with ischemic HF.
Sections du résumé
BACKGROUND
Heart failure (HF) is nowadays classified as HF with reduced ejection fraction (HFrEF), HF with mildly reduced EF (HFmrEF), and HF with preserved EF (HFpEF). Endothelial dysfunction (assessed by flow-mediated dilatation [FMD]), increased arterial stiffness (assessed by carotid-femoral pulse-wave velocity [PWV]), and galectin-3, a biomarker of myocardial fibrosis, have been linked to major adverse cardiovascular events (MACE) in patients with ischemic HF.
METHODS
In this study we prospectively enrolled 340 patients with stable ischemic HF. We assessed the brachial artery FMD, carotid-femoral PWV, and galectin-3 levels, and patients were followed up for MACE according to HF group.
RESULTS
Interestingly, the FMD values exhibited a stepwise improvement according to left ventricular ejection fraction (LVEF) (HFrEF: 4.74 ± 2.35% vs. HFmrEF: 4.97 ± 2.81% vs. HFpEF: 5.94 ± ± 3.46%, p = 0.01), which remained significant after the evaluation of possible confounders including age, sex, cardiovascular risk factors, and number of significantly stenosed epicardial coronary arteries (b coefficient: 0.990, 95% confidence interval: 0.166-1.814, p = 0.019). Single-vessel coronary artery disease was more frequent in the group of HFpEF (HFrEF: 56% vs. HFmrEF: 64% vs. HFpEF: 73%, p = 0.049). PWV did not display any association with LVEF. Patients who presented MACE exhibited worse FMD values (4.51 ± 2.35% vs. 5.32 ± 2.67%, p = 0.02), and the highest tertile of galectin-3 was linked to more MACEs (36% vs. 5.9%, p = 0.01).
CONCLUSIONS
Flow-mediated dilatation displayed a linear improvement with LVEF in patients with ischemic HF. Deteriorated values are associated with MACE. Higher levels of galectin-3 might be used for risk stratification of patients with ischemic HF.
Identifiants
pubmed: 35975796
pii: VM/OJS/J/88256
doi: 10.5603/CJ.a2022.0074
pmc: PMC10635724
doi:
Substances chimiques
Galectin 3
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
725-733Références
J Nucl Cardiol. 2017 Oct;24(5):1759-1792
pubmed: 28608183
Medicine (Baltimore). 2018 Jun;97(24):e11093
pubmed: 29901624
J Am Coll Cardiol. 2017 Aug 8;70(6):776-803
pubmed: 28461007
Am Heart J. 2013 Jun;165(6):995-9
pubmed: 23708172
J Am Coll Cardiol. 2001 Jan;37(1):195-200
pubmed: 11153738
Clin Res Cardiol. 2011 Jun;100(6):515-21
pubmed: 21212968
PLoS One. 2019 Aug 5;14(8):e0220183
pubmed: 31381586
Eur J Heart Fail. 2016 Mar;18(3):242-52
pubmed: 26727047
Hypertension. 2010 Mar;55(3):799-805
pubmed: 20065155
J Hypertens. 2008 Oct;26(10):2001-7
pubmed: 18806624
Eur J Heart Fail. 2021 Mar;23(3):352-380
pubmed: 33605000
Eur J Heart Fail. 2009 Jun;11(6):588-93
pubmed: 19406838
Int J Cardiol. 2015;190:308-14
pubmed: 25935618
J Am Soc Echocardiogr. 2012 Apr;25(4):454-9
pubmed: 22243999
Heart. 2005 Apr;91(4):553-8
pubmed: 15772232
J Am Heart Assoc. 2015 Nov 23;4(11):
pubmed: 26597152
J Am Coll Cardiol. 2002 Jan 16;39(2):257-65
pubmed: 11788217
Eur Heart J. 2013 May;34(19):1404-13
pubmed: 23095984
Curr Vasc Pharmacol. 2019;17(4):396-400
pubmed: 29968538
Am J Pathol. 2016 May;186(5):1114-27
pubmed: 26948424
Int J Cardiol. 2012 Jul 26;158(3):417-22
pubmed: 21371765
Lancet Public Health. 2019 Aug;4(8):e406-e420
pubmed: 31376859
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
Circ Heart Fail. 2012 Nov;5(6):720-6
pubmed: 22936826
J Cardiovasc Pharmacol. 1986;8 Suppl 1:S36-52
pubmed: 2422492
Eur J Heart Fail. 2009 Aug;11(8):765-70
pubmed: 19578078
J Am Coll Cardiol. 2018 Aug 7;72(6):591-601
pubmed: 30071987
Circulation. 2015 Feb 10;131(6):550-9
pubmed: 25552356
Eur J Heart Fail. 2017 Dec;19(12):1574-1585
pubmed: 28386917
Circulation. 2003 Feb 11;107(5):714-20
pubmed: 12578874
Herz. 2016 Dec;41(8):655-663
pubmed: 27858115
JACC Heart Fail. 2018 Aug;6(8):633-639
pubmed: 29525327
Lancet. 2013 Feb 23;381(9867):639-50
pubmed: 23439103
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Eur Heart J. 2019 Jul 1;40(26):2155-2163
pubmed: 30957868
J Geriatr Cardiol. 2018 Nov;15(11):687-694
pubmed: 30534143
Atherosclerosis. 2013 Apr;227(2):367-72
pubmed: 23433403
JACC Heart Fail. 2018 Aug;6(8):678-685
pubmed: 30007560
Minerva Cardioangiol. 2016 Dec;64(6):595-602
pubmed: 27119370